Vanguard Group Inc. Buys 281,789 Shares of Accuray Incorporated (ARAY)
Vanguard Group Inc. grew its stake in Accuray Incorporated (NASDAQ:ARAY) by 4.4% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,728,919 shares of the medical equipment provider’s stock after purchasing an additional 281,789 shares during the quarter. Vanguard Group Inc. owned approximately 8.11% of Accuray worth $31,962,000 at the end of the most recent reporting period.
Several other hedge funds also recently bought and sold shares of ARAY. Spark Investment Management LLC lifted its holdings in shares of Accuray by 138.1% in the second quarter. Spark Investment Management LLC now owns 406,200 shares of the medical equipment provider’s stock valued at $1,929,000 after purchasing an additional 235,600 shares in the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Accuray by 27.6% in the first quarter. Dimensional Fund Advisors LP now owns 858,013 shares of the medical equipment provider’s stock valued at $4,076,000 after purchasing an additional 185,519 shares in the last quarter. Teachers Advisors LLC lifted its holdings in shares of Accuray by 83.5% in the second quarter. Teachers Advisors LLC now owns 235,490 shares of the medical equipment provider’s stock valued at $1,119,000 after purchasing an additional 107,178 shares in the last quarter. Global X Management Co. LLC lifted its holdings in shares of Accuray by 238.2% in the second quarter. Global X Management Co. LLC now owns 151,589 shares of the medical equipment provider’s stock valued at $720,000 after purchasing an additional 106,773 shares in the last quarter. Finally, Royce & Associates LP lifted its holdings in shares of Accuray by 6.7% in the second quarter. Royce & Associates LP now owns 1,676,077 shares of the medical equipment provider’s stock valued at $7,961,000 after purchasing an additional 105,000 shares in the last quarter. Institutional investors own 74.87% of the company’s stock.
In related news, COO Kelly Londy sold 99,136 shares of the stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $4.24, for a total transaction of $420,336.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 3.90% of the company’s stock.
Shares of Accuray Incorporated (NASDAQ:ARAY) opened at $4.55 on Friday. The company has a debt-to-equity ratio of 2.44, a quick ratio of 0.72 and a current ratio of 1.48. Accuray Incorporated has a 52-week low of $3.60 and a 52-week high of $6.00.
Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Tuesday, October 24th. The medical equipment provider reported ($0.07) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.09) by $0.02. The company had revenue of $91.00 million during the quarter, compared to the consensus estimate of $88.26 million. Accuray had a negative return on equity of 55.18% and a negative net margin of 7.49%. Accuray’s revenue was up 5.2% on a year-over-year basis. During the same period last year, the business posted ($0.12) earnings per share. research analysts predict that Accuray Incorporated will post -0.18 earnings per share for the current fiscal year.
A number of research firms have recently weighed in on ARAY. Cowen and Company restated a “buy” rating and issued a $9.00 target price on shares of Accuray in a report on Friday, October 27th. Zacks Investment Research lowered Accuray from a “buy” rating to a “hold” rating in a report on Wednesday, October 25th. BTIG Research restated a “hold” rating on shares of Accuray in a report on Thursday, August 24th. Royal Bank Of Canada restated a “hold” rating and issued a $5.00 target price on shares of Accuray in a report on Thursday, August 24th. Finally, Jefferies Group LLC decreased their price target on Accuray from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday, August 23rd. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have issued a buy rating to the company. Accuray currently has a consensus rating of “Hold” and a consensus price target of $6.29.
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Want to see what other hedge funds are holding ARAY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Accuray Incorporated (NASDAQ:ARAY).
Receive News & Stock Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related stocks with our FREE daily email newsletter.